Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31010217 | 0.95 | HRH3 (0.57) | HRH3TSHRALDH1A1MAPK1HPGD | |
| SCHEMBL30635452 | 0.90 | HRH3 (0.52) | HRH3ALDH1A1 | |
| SCHEMBL24571880 | 0.83 | HRH3 (0.68) | HRH3TSHRALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL30635456 | 0.82 | HRH3 (0.47) | HRH3POLB | |
| SCHEMBL25177979 | 0.79 | TAAR1 (0.55) | HRH3ALDH1A1SMN1; SMN2 | |
| SCHEMBL15260468 | 0.77 | HRH3 (0.56) | HRH3TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL14606256 | 0.77 | HRH3 (0.52) | HRH3ALDH1A1SMN1; SMN2 | |
| SCHEMBL30635490 | 0.75 | TAAR1 (0.40) | TSHRPOLBAOC3SMN1; SMN2 | |
| SCHEMBL21565579 | 0.74 | HRH3 (0.55) | HRH3SMN1; SMN2 | |
| SCHEMBL26157316 | 0.74 | KMT2A (0.45) | HRH3TSHRPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023229380-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | disclosed |